a·lac·ri·ty [uh-lak-ri-tee] cheerful readiness, promptness, or willingness
Europe: London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
USA: Cambridge Innovation Center 1 Broadway, 14th Floor Kendall Square, Cambridge MA 02142

Our People

Rob Johnson

BSc

Prior to forming Alacrita, Rob Johnson was Head of Business Development at Onyvax Ltd, a biotechnology company specialising in the development of complex biopharmaceuticals to treat cancer. At Onyvax he supported scientific teams with the identification, negotiation and management of R&D collaborations and out-sourcing contracts. He also had primary responsibility for in-licensing, out-licensing and M&A.

At Alacrita, Rob has led and managed a number of consulting projects across broad functional disciplines, including regulatory affairs, clinical development and business development. Projects in which Rob has played a leading role include:

  • In-licensing support and due diligence for a North American company searching for early stage oncology assets
  • Biologics strategy for an established US biotech company
  • Pharma-partnering roadmap for a diagnostics company
  • Strategic planning support for a leading supplier of histocompatibility and immunogenetics services.
  • Valuation of an oncology drug to support a royalty monetisation transaction
  • Valuation model, incorporating monte carlo simulation, of an early stage oncology therapy to support a license negotiation with big pharma
  • Business development and marketing roadmap for a vaccine services provider
  • Licensing of a technology platform from a university into a new start-up
  • Due diligence on a cell therapy reagents company
  • Commercial due diligence on a novel diabetes product
  • Literature review and KOL interviews to develop clinical strategy for a novel oncology drug
  • Business plan and investor presentation to support a Series B financing for a European oncology company
  • Biotechnology strategy and biosafety regulatory framework for an emerging economy
  • Set out a commercialisation roadmap for a novel, recombinant biomaterial

Rob Johnson established Alacrita in 2009 and opened Alacrita’s US office in Cambridge, Massachusetts in 2012.

He has a BSc in biochemistry from the University of Nottingham.

« Back to Our People